N,N-Diphenylaminoacetamid | 36602-07-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N-Diphenylaminoacetamid
• 英文别名: diphenylglycinamide；Diphenylglycineamide；2-(N-phenylanilino)acetamide
• CAS: 36602-07-0
• 化学式: C₁₄H₁₄N₂O
• 分子量: 226.278
• InChiKey: MUTSJHVOFFHGGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Isoxazole Derivatives and Use Thereof
  申请人：Cho Jeong Woo

  公开号：US20090131336A1

  公开（公告）日：2009-05-21

  Disclosed herein are isoxazole derivaties and uses thereof. Serving as agonists of Wnt, the isoxazole derivatives activate Wnt/β-catenin signaling and thus can be used in the treatment and prevention of diseases related to the signal transduction. Also, pharmaceutically acceptable salts of the isoxazole derivatives are disclosed.

  本文披露了异噁唑衍生物及其用途。作为Wnt的激动剂，异噁唑衍生物激活Wnt/β-连环蛋白信号传导，因此可用于治疗和预防与信号传导相关的疾病。此外，还披露了异噁唑衍生物的药用盐。
• Novel thrombin inhibitors, the preparation and use thereof
  申请人：Boehm Hans-Joachim

  公开号：US20060111553A1

  公开（公告）日：2006-05-25

  Compounds of the formula and the salts thereof with physiologically tolerated acids and the stereoisomers thereof, in which the substituents have the meanings stated in the description, are described. Also disclosed are intermediates for their preparation. The compounds are suitable for controlling diseases.

  本文描述了化学式及其生理耐受酸盐和立体异构体，其中取代基具有所述描述中的含义。还公开了其制备中间体。这些化合物适用于控制疾病。
• Use of prophenytoin for preparing pharmaceutical preparations for treating stroke and cerebral ischemia
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0427925A2

  公开（公告）日：1991-05-22

  The present invention relates to a new therapeutic indication of known derivatives of phenytoin or a stable pharmaceutical composition of the phenytoin prodrug which is now known as fosphenytoin sodium. More particularly, the present invention concerns a method of preparing pharma­ceutical compositions for treating cerebral ischemia or stroke in a human by using the derivatives of phenytoin, preferably 3-(hydroxy-methyl)-5,5-­diphenylhydantoin phosphate ester disodium salt or a prodrug of phenytoin as active compounds. The preferred compound is also variously known as the fosphenytoin sodium; 5,5-diphenyl-3-­[(phosphonooxy)methyl]-2,4-imidazolidinedione disodium salt; 3-phosphoryl-oxymethyl-5,5-­diphenylhydantoin disodium salt; or 3-­(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester

  本发明涉及一种已知苯妥英衍生物或苯妥英原药（现称为磷苯妥英钠）的稳定药物组合物的新治疗适应症。更具体地说，本发明涉及一种使用苯妥英衍生物，优选 3-（羟甲基）-5,5-二苯基海因磷酸酯二钠盐或苯妥英原药作为活性化合物，制备治疗人类脑缺血或中风的药物组合物的方法。优选的化合物也被称为磷苯妥英钠；5,5-二苯基-3-[（磷酰氧基）甲基]-2,4-咪唑烷二酮二钠盐；3-磷酰-氧甲基-5,5-二苯基海因二钠盐；或 3-（羟甲基）-5,5-二苯基海因磷酸酯二钠盐。
• [EN] C-MYC PROTEIN INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF<br/>[FR] INHIBITEUR DE PROTÉINE C-MYC, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 一种c-Myc蛋白抑制剂及其制备方法和用途
  申请人：SUZHOU KINTOR PHARMACEUTICALS INC

  公开号：WO2021004391A1

  公开（公告）日：2021-01-14

  涉及一类c-Myc蛋白抑制剂及其制备方法和用途，所述c-Myc蛋白抑制剂可选择性的抑制c-Myc蛋白，因此，可用于c-Myc蛋白失调的相关疾病，如癌症、心脑血管疾病、病毒感染相关疾病等的预防和治疗。
• STABLE PHARMACEUTICAL COMPOSITION OF 3-(HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER
  申请人：THE DU PONT MERCK PHARMACEUTICAL COMPANY

  公开号：EP0473687A1

  公开（公告）日：1992-03-11